Biotechnology research firm Creative Biolabs has unveiled several innovative strategies for investigating and combating COVID-19, focusing on the virus’s critical spike protein mechanism. The company’s multifaceted approach addresses key challenges in drug design, vaccine development, and viral neutralization testing.
Central to their research is the development of a pseudovirus neutralization assay, which allows researchers to test potential antiviral drugs and antibodies with enhanced safety and efficiency. Unlike traditional methods requiring biosafety level 3 laboratories, this technique uses genetically engineered viruses that can infect cells without replicating, significantly reducing experimental risks.
The company has also created stable cell lines expressing the SARS-CoV-2 spike protein, which serve multiple research purposes. These cell lines facilitate vaccine development by providing antigen expression vectors, enable neutralizing antibody screening, and support drug research by allowing testing of molecules designed to block viral infection.
Recognizing the ongoing challenge of emerging virus variants, Creative Biolabs has developed a virus-like particle (VLP) vaccine platform utilizing a modified vaccinia Ankara (MVA) vector. This platform generates in vivo virus-like particles containing the SARS-CoV-2 spike protein, which can induce strong immune responses without infection risks.
The VLP approach offers significant advantages, as these particles mimic viral external structures while lacking a viral genome. By combining the immunogenicity of VLPs with MVA’s safety profile, researchers can explore more versatile and effective vaccine candidates.
These technological innovations represent critical advancements in understanding and potentially mitigating the SARS-CoV-2 virus. By providing researchers with sophisticated tools for spike protein analysis, Creative Biolabs contributes to the global scientific effort to develop targeted therapeutic and preventative strategies against COVID-19.
This news story relied on a press release distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Creative Biolabs Advances COVID-19 Research with Innovative Spike Protein Technologies.